TransCode Therapeutics, Inc. (RNAZ) NASDAQ
6.24
+0.125(+2.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.24
+0.125(+2.04%)
Currency In USD
Address
6 Liberty Square
Boston, MA 02109
United States of America (the)
Phone
857-837-3099
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
July 08, 2021
| Name | Title | Pay | Year Born |
| Philippe Calais | Chief Executive Officer & Executive Chairman of the Board | 566,116 | 1959 |
| Thomas A. Fitzgerald | Chief Financial Officer, President, Vice President of Administration & Director | 1.07M | 1952 |
| Zdravka Medarova | Scientific Co-Founder & Chief Scientific Officer | 0 | 1975 |
| Anna Moore | Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board | 0 | 1962 |
| Daniel R. Vlock | Chief Medical Officer | 0 | 1952 |
| Susan Duggan | Senior Vice President of Operations | 0 | N/A |
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.